166952-77-8

Basic information

• Product Name: Acetic acid, 2,2'-[(4-acetyl-1,2-phenylene)bis(oxy)]bis-, dimethyl ester
• CAS NO: 166952-77-8
• Molecular Formula: C14H16O7
• Molecular Weight: 296.277
• Mol File: 166952-77-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Acetic acid, 2,2'-[(4-acetyl-1,2-phenylene)bis(oxy)]bis-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, 2,2'-[(4-acetyl-1,2-phenylene)bis(oxy)]bis-, dimethyl ester(166952-77-8)
• EPA Substance Registry System: Acetic acid, 2,2'-[(4-acetyl-1,2-phenylene)bis(oxy)]bis-, dimethyl ester(166952-77-8)

Safety Data

• Hazardous Substances Data: 166952-77-8(Hazardous Substances Data)

Upstream product

• 1197-09-7 1-(3,4-dihydroxyphenyl)ethan-1-one 
• 96-34-4 methyl chloroacetate 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 214057-60-0 [2-methoxycarbonylmethoxy-5-(2-methyl-[1,3]dioxolan-2-yl)-phenoxy]-acetic acid methyl ester 
• 166952-78-9 methyl 2-[4-(2-bromoacetyl)-2-methoxycarbonylmethoxyphenoxy]acetate 
• 1527500-97-5 1-(2-(3,4-Bis(2-methoxy-2-oxoethoxy)phenyl)-2-oxoethyl)pyridazin-1-ium bromide 
• 1527501-03-6 2-(2-(3,4-Bis(2-methoxy-2-oxoethoxy)phenyl)-2-oxoethyl)phthalazin-2-ium bromide 
• 349458-67-9 ({2-[2-[2-(bis-tert-butoxycarbonylmethyl-amino)-ethoxy]-5-(7-diethylamino-2-oxo-2H-chromene-3-carbonyl)-phenoxy]-ethyl}-tert-butoxycarbonylmethyl-amino)-acetic acid tert-butyl ester 
• 338740-60-6 methanesulfonic acid 2-[4-(7-diethylamino-2-oxo-2H-chromene-3-carbonyl)-2-(2-methanesulfonyloxyethoxy)-phenoxy]-ethyl ester 
• 338740-56-0 3-[3,4-bis-(2-hydroxy-ethoxy)-benzoyl]-7-diethylamino-chromen-2-one 
• 113393-37-6 2-[2-(2-hydroxy-ethoxy)-5-(2-methyl-[1,3]dioxolan-2-yl)-phenoxy]-ethanol 
• 349458-66-8 ({2-[2-[2-(bis-tert-butoxycarbonylmethyl-amino)-ethoxy]-5-(5,7-dimethoxy-2-oxo-2H-chromene-3-carbonyl)-phenoxy]-ethyl}-tert-butoxycarbonylmethyl-amino)-acetic acid tert-butyl ester 
• 349458-65-7 ({2-[2-[2-(bis-tert-butoxycarbonylmethyl-amino)-ethoxy]-5-(7-methoxy-2-oxo-2H-chromene-3-carbonyl)-phenoxy]-ethyl}-tert-butoxycarbonylmethyl-amino)-acetic acid tert-butyl ester 
• 349458-64-6 ({2-[2-[2-(bis-tert-butoxycarbonylmethyl-amino)-ethoxy]-5-(2-oxo-2H-chromene-3-carbonyl)-phenoxy]-ethyl}-tert-butoxycarbonylmethyl-amino)-acetic acid tert-butyl ester 
• 338740-59-3 methanesulfonic acid 2-[5-(5,7-dimethoxy-2-oxo-2H-chromene-3-carbonyl)-2-(2-methanesulfonyloxyethoxy)-phenoxy]-ethyl ester 
• 338740-58-2 methanesulfonic acid 2-[2-(2-methanesulfonyloxyethoxy)-5-(7-methoxy-2-oxo-2H-chromene-3-carbonyl)-phenoxy]-ethyl ester 
• 338740-57-1 methanesulfonic acid 2-[2-(2-methanesulfonyloxyethoxy)-5-(2-oxo-2H-chromene-3-carbonyl)-phenoxy]-ethyl ester 

Relevant articles and documents

Synthesis and in vitro analysis of novel dihydroxyacetophenone derivatives with antimicrobial and antitumor activities

Herein we report a feasible study concerning the design, syntheses and in vitro antimicrobial and antitumoral activities of some novel compounds with dihydroxyacetophenone (DA) moiety. An efficient and general method for the preparation of diazine with dihydroxyacetophenone (DDA) skeleton under conventional thermal heating (TH), microwave (MW) and ultrasounds (US) irradiation is presented. Antimicrobial and antitumoral tests prove that some dihydroxyacetophenone compounds (the brominated derivatives BrDA 3) have a significant biological activity. It is also to be pointed out that, basically all the dihydroxyacetophenone derivatives proved to have a powerful antibacterial activity against drug resistant Gram-negative strain Pseudomonas aeruginosa ATCC 27853. Of particular interest could be the excellent antibacterial activity of our dihydroxyacetophenone compounds against drug resistant Gram-negative strain Pseudomonas aeruginosa.

Heterocyclic derivatives

Compounds of formula I STR1 and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R13, M2, X1, Z1, Z1a, X2 and A1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Novel intermediates are also disclosed.